Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT).
about
Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesEfficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review.Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primatesLiraglutide Exerts Antidiabetic Effect via PTP1B and PI3K/Akt2 Signaling Pathway in Skeletal Muscle of KKAy Mice.Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.Liraglutide as add-on therapy to insulin in type 2 diabetes mellitus: a retrospective, observational study from a daily clinical practice setting in SwitzerlandIDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test.Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus.Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden.Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial.Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US.Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps.Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations.Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis.Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategies.Factors associated with insulin-induced weight gain in an Australian type 2 diabetes outpatient clinic.β cell membrane remodelling and procoagulant events occur in inflammation-driven insulin impairment: a GLP-1 receptor dependent and independent control.Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) randomized cSatisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial.Comparison of non-insulin antidiabetic agents as an add-on drug to insulin therapy in type 2 diabetes: a network meta-analysis.Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification.
P2860
Q28067465-CB85D5A5-BFC6-4FC5-AB57-46AADBED62B8Q30240808-DF0AA688-418D-4163-A625-FC12617BCA23Q30368984-C0C1E7A3-5783-4B57-AC7D-D9CBF0089D69Q34087944-ADBBA2CD-8518-46A8-AE85-6B6FE5DAF222Q35080171-46898636-8C4C-4808-91E3-ECD73184C8ACQ35217925-0F0F3AC2-7254-4969-9684-33AFD4A03F08Q36638917-504D2C7C-0836-4C9A-834E-61DC88301AFBQ36757419-EB711F1E-9FFC-43EA-8FF2-C6FF7213191BQ36989711-9BDB04E9-F84F-4C81-A97F-9B5A217AF0ADQ37320537-3A28F8A0-00AA-4043-A86A-47DDC27BED7FQ37538487-A7EE3EEF-588C-474F-BB22-55C900F9CDB7Q38246691-344EC4C9-4B9D-4D1B-A758-E774AF7144A9Q38270132-05ACFF16-0583-4E73-88D1-5D8C7FB4D827Q38634679-2092C5FE-5A6E-47C2-BDB6-8264927B94A3Q38907259-C3E6BD9B-A456-4EA5-AFFD-FBD99F699E8FQ39309680-008A36A6-5EFD-4841-A6FF-33179BC3C99CQ39350860-7E01E108-3C14-4837-B7F6-1827A7313A28Q39808542-E0F49675-6D34-4FA1-9B29-9FD5C028002FQ42109004-B761E140-D644-4897-8A35-2FB2D19ED356Q47348380-EBDB6609-A561-451F-A493-EBA3D5BC7F91Q48122512-753F2AC4-7BE0-480C-9C85-BE1ED07A5965Q51245889-1620C54E-112A-43F0-96E8-7A433DCE8D07Q51246605-A3414D41-94AE-4527-AA3A-760FD0AE015C
P2860
Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT).
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Liraglutide reverses pronounce ...... ised clinical trial (ELEGANT).
@en
Liraglutide reverses pronounce ...... ised clinical trial (ELEGANT).
@nl
type
label
Liraglutide reverses pronounce ...... ised clinical trial (ELEGANT).
@en
Liraglutide reverses pronounce ...... ised clinical trial (ELEGANT).
@nl
prefLabel
Liraglutide reverses pronounce ...... ised clinical trial (ELEGANT).
@en
Liraglutide reverses pronounce ...... ised clinical trial (ELEGANT).
@nl
P2093
P2860
P921
P1433
P1476
Liraglutide reverses pronounce ...... ised clinical trial (ELEGANT).
@en
P2093
Bastiaan E de Galan
Cees J Tack
Gerald M M Vervoort
Helena M de Wit
Henry J Jansen
Wim J C de Grauw
P2860
P2888
P304
P356
10.1007/S00125-014-3302-0
P577
2014-06-20T00:00:00Z